Breast cancer survivors with luminal type tumors (i.e., estrogen receptor positive [ER+], progesterone receptor positive [PR+), and human epidermal growth factor receptor 2 negative [HER2-)) are at a higher risk of late recurrence (7). Here, PGR is linked to breast carcinoma.